Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Prepaid Assets: 2009-2025

Historic Prepaid Assets for Lifecore Biomedical (LFCR) over the last 16 years, with May 2025 value amounting to $1.5 million.

  • Lifecore Biomedical's Prepaid Assets rose 1.04% to $1.5 million in Q2 2025 from the same period last year, while for May 2025 it was $1.5 million, marking a year-over-year increase of 1.04%. This contributed to the annual value of $1.5 million for FY2025, which is 1.04% up from last year.
  • Latest data reveals that Lifecore Biomedical reported Prepaid Assets of $1.5 million as of Q2 2025, which was down 42.94% from $2.5 million recorded in Q1 2025.
  • Lifecore Biomedical's 5-year Prepaid Assets high stood at $5.9 million for Q1 2021, and its period low was $1.3 million during Q3 2021.
  • In the last 3 years, Lifecore Biomedical's Prepaid Assets had a median value of $1.9 million in 2024 and averaged $2.6 million.
  • Its Prepaid Assets has fluctuated over the past 5 years, first tumbled by 90.50% in 2021, then surged by 195.32% in 2023.
  • Over the past 5 years, Lifecore Biomedical's Prepaid Assets (Quarterly) stood at $1.4 million in 2021, then rose by 16.10% to $1.7 million in 2022, then rose by 10.28% to $1.8 million in 2023, then soared by 56.42% to $2.9 million in 2024, then increased by 1.04% to $1.5 million in 2025.
  • Its Prepaid Assets was $1.5 million in Q2 2025, compared to $2.5 million in Q1 2025 and $2.9 million in Q4 2024.